Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.20.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating Expenses    
Research and development expenses $ 501,771 $ 484,750
General and administrative expenses 484,353 397,766
Operating Loss (986,124) (882,516)
Other Income (Expense)    
Interest expense (17,170) (4,600)
Interest income 829 5,985
Net Operating Loss Before Income Tax Benefit (1,002,465) (881,131)
Income Tax Benefit 128,129 130,299
Net Loss $ (874,336) $ (750,832)
Net Loss Per Common Share - Basic and Diluted $ (0.16) $ (0.14)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted 5,515,447 5,525,009